BRIEF—First drug from Eisai-UCL Alzheimer's collaboration enters trials

The first drug candidate from the research collaboration between Eisai, the Japanese pharma company, and University College London (UCL), is to enter Phase I trials in Alzheimer’s disease.

E2814 is set to be tested in humans for the first time in early 2019 and is designed to target tau ‘seeds’ to potentially slow the course of the disease.

The partners have been collaborating since 2012, initially for a period of six years, and that has been extended for a further five years until 2023.